Literature DB >> 15725247

The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine.

Q Xia1, S Yang, S Q Zhang, B Chen, D B Wang, Q X Zhu, Y Wang, K L Yan, P P He, X J Zhang.   

Abstract

It has been shown that many antihistamines may have anti-inflammatory activity in addition to being H1 antagonists. Mizolastine (MIZ), a novel antihistamine, might also have anti-angiogenesis properties. In this study, we investigated the influence of MIZ on proangiogenesis factors, vascular endothelial cell growth factor (VEGF), tumour necrosis factor (TNF)-alpha and keratinocyte-derived chemokine (KC) in murine mast cells by using ELISA and RT-PCR, as compared with dexamethasone (DEX) and loratadine (LOR). Our results show that MIZ is effective in the inhibition of KC, VEGF and TNF-alpha release induced by an IgE-dependent mechanism, in a time- and dose-dependent manner. The differences between the inhibitory effects of the three drugs on these proangiogenic factors were rather subtle. Semiquantitative analysis using RT-PCR showed that the three drugs significantly reduced VEGF165, VEGF120, TNF-alpha and KC mRNA expression. Statistical results revealed that the effect of DEX on VEGF165 mRNA was different from that of MIZ or LOR (P < 0.01) and the differences between the three drugs on VEGF120, TNF-alpha and KC mRNA were not statistically significant (P > 0.05). These findings raise the possibility that MIZ can mediate anti-angiogenesis activity and that the effect may depend not only on the inhibition on the levels of cytokine proteins but also at the mRNA level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725247     DOI: 10.1111/j.1365-2230.2005.01721.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  7 in total

Review 1.  Histamine H1-receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases.

Authors:  T Okamoto; S Iwata; K Ohnuma; N H Dang; C Morimoto
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

2.  Evidence for the contribution of tumour necrosis factor in oedema formation induced by histamine in the hind paw of the rat.

Authors:  K Kalokasidis; D Molyva; V Mirtsou; B Kokkas; A Goulas
Journal:  Inflamm Res       Date:  2009-05-12       Impact factor: 4.575

Review 3.  Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-12

4.  VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model.

Authors:  R Patruno; N Arpaia; C D Gadaleta; L Passantino; N Zizzo; A Misino; N M Lucarelli; A Catino; P Valerio; D Ribatti; G Ranieri
Journal:  J Cell Mol Med       Date:  2008-04-18       Impact factor: 5.310

5.  Mast Cell Activation Triggered by Retrovirus Promotes Acute Viral Infection.

Authors:  Shu-Ting Song; Meng-Li Wu; Hai-Jiao Zhang; Xiao Su; Jian-Hua Wang
Journal:  Front Microbiol       Date:  2022-02-07       Impact factor: 5.640

6.  SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury.

Authors:  Meng-Li Wu; Feng-Liang Liu; Jing Sun; Xin Li; Xiao-Yan He; Hong-Yi Zheng; Yan-Heng Zhou; Qihong Yan; Ling Chen; Guo-Ying Yu; Junbiao Chang; Xia Jin; Jincun Zhao; Xin-Wen Chen; Yong-Tang Zheng; Jian-Hua Wang
Journal:  Signal Transduct Target Ther       Date:  2021-12-17

7.  Vitamin K2 Ameliorates Damage of Blood Vessels by Glucocorticoid: a Potential Mechanism for Its Protective Effects in Glucocorticoid-induced Osteonecrosis of the Femoral Head in a Rat Model.

Authors:  Yuelei Zhang; Junhui Yin; Hao Ding; Changqing Zhang; You-Shui Gao
Journal:  Int J Biol Sci       Date:  2016-04-28       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.